TROP2 CAR engineered IL15-transduced NK cell therapy (MD Anderson Cancer Center)

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameTROP2 CAR engineered IL15-transduced NK cell therapy (MD Anderson Cancer Center)

Drug Alias NameTROP2-CAR-NK Cells (MD Anderson Cancer Center)TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells (MD Anderson Cancer Center)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionNatural killer cell replacementsAnti-Trop-2

TargetsTumor-associated calcium signal transducer 2

Therapy Area/IndicationsSolid tumoursNeoplasm, ResidualColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBellicum Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesBellicum Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursNeoplasm, ResidualColorectal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A